1. Thermography-controlled wIRA superficial hyperthermia new at the Klinikum Stuttgart – Stuttgart Cancer Center (SCC)
The hydrosun®TWH1500 hyperthermia device has just been installed at the Klinikum Stuttgart – Stuttgart Cancer Center Tumorzentrum Eva Mayr-Stihl.
Excerpt from the article in the Stuttgarter Zeitung (StZ) of July 10, 2025 (translation by us):
"The local recurrence of breast cancer poses a significant therapeutic challenge, particularly in cases of irresectability and prior radiation therapy. Effective tumor control through repeated radiation therapy is associated with risks in such cases – in addition, patients in advanced stages often no longer respond adequately to the therapies. Even patients with pre-existing conditions or older patients are sometimes not expected to undergo aggressive systemic therapy."
"When side effects are disproportionate to the expected therapeutic benefit, new approaches are needed – and we have found precisely this with superficial hyperthermia in this special patient group," explains Dr. Julia Gottfried, senior physician at the Center for Integrative Tumor Medicine at the Klinikum Stuttgart."
2. ICHO – International Congress on Hyperthermic Oncology – September 2025 in Seoul / Korea
ICHO 2025 will take place in Seoul from September 10-13 as a joint event of ASHO (Asian Society for Hyperthermic Oncology), ESHO (European Society for Hyperthermic Oncology), and the North American STM (Society for Thermal Medicine). Heckel is a sponsor and, together with its Korean partner Biomedisyn, an exhibitor.
Dr Markus Notter, Lindenhofspital Bern, will give an oral presentation on „Contact-free WRA-hyperthermia combined with hypofractionated radiotherapy of non-melanoma skin cancers“.
For the program and registration, see: ICHO2025 3. Fever-range whole-body hyperthermia for post-COVID/post-vaccine-syndrom
The diagnosis and treatment of post-COVID and post-vaccine syndrome is one of the major challenges facing medicine today. Fever-range whole-body hyperthermia (FR-WBH) has emerged as an important treatment module in various hospitals and clinics.
Two publications on this topic have been published this year:
[GERMAN] Matthes H: Diagnostik und Therapie bei Post-COVID-19 und Post-Vaccination-Syndrom - Ein Erfahrungsbericht aus dem Krankenhaus Havelhöhe Berlin. Deutsche Zeitschrift für Akupunktur | Ausgabe 1/2025. OPEN ACCESS.
At the apheresis center there, whole-body hyperthermia is used particularly for the treatment of exosomal spicopathy and to enhance immunoadsorption apheresis in severe cases with GPCR autoantibody findings.
Vagedes J et al: Whole-body hyperthermia as part of a multimodal treatment for patients with post-covid syndrome – a case series. Int J Hyperthermia, 42(1). OPEN ACCESS
A retrospective analysis of 46 patients treated with a multimodal therapy concept including fever-range whole-body hyperthermia at the Paracelsuskrankenhaus Bad Liebenzell showed significant improvements in quality of life. Data were collected using the validated FACIT-F and FIS-D questionnaires at admission, discharge, and 4 weeks after discharge.
4. Does fever range-whole-body hyperthermia improve the likelihood of the abscopal effect of radiotherapy?
To date, the use of fever-range whole-body hyperthermia (FR-WBH) in oncology has been largely limited to the field of “Integrative Oncology”. Positive clinical experiences, results from basic research, and the important role of immunology in modern oncology suggest significant synergistic potential. A prerequisite for broad clinical application is an increase in the clinical level of evidence. The POWER study currently underway at Charité, where FR-WBH is being tested in various tumor entities in combination with standard therapies, is intended to provide further insights into the most promising indications and co-interventions.
A review published at the end of 2024 is now of interest.
Van Dieren et al.: Combined Radiotherapy and Hyperthermia: A Systematic Review of Immunological Synergies for Amplifying Radiation-Induced Abscopal Effects. Cancers (Basel).
2024 Oct 30;16(21):3656. OPEN ACCESS.
The abscopal effect of radiotherapy, which sometimes leads to tumor remission even in untreated areas, is based on the activation of the systemic anti-tumor immune response by local therapy. This review “explores how heating the body (hyperthermia) alongside radiotherapy may improve the likelihood of this effect”. Interestingly, the authors “suggest the combination of local radiotherapy with fever-range whole-body hyperthermia to optimally enhance the chances of triggering the abscopal effect mediated by the immune system”.
5. New publication with detailed consideration of wIRA-absorption in malignant and healthy tissue
Piazena H, Vaupel P: Hyperhydration of breast and skin cancers: effects on thermophysical tissue properties in clinical hyperthermia with water-filtered infrared-A radiation (wIRA) - an updated review. Int J Hyperthermia. 2025 Dec;42(1):2519352. Epub 2025 Jul 10. OPEN ACCESS
This publication discusses in detail the absorption of wIRA radiation and tissue heating by wIRA in malignant and healthy tissue, with particular attention to their varying water content. “These data indicate high efficacy of superficial wIRA-hyperthermia in clinical oncology when exposed to composite tissues with highly variable water and fat contents.”
※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 게시한 것임을 알립니다.
